Antonio Gonzalez Martín, MD, discusses the results from the phase III PRIMA study, which evaluated the PARP inhibitor niraparib versus placebo as a frontline treatment of patients with newly diagnosed ovarian cancer who responded to platinum-based chemotherapy.
